Hangzhou SoliPharma Co., Ltd. ("SoliPharma") today announced an exclusive global development, license and supply collaboration for a complex topical dermatology product with Adalvo, a leading global pharmaceutical company specializing in the development and commercialization of complex generics, 505(b)2, peptides and biosimilars.
The product, a high-barrier, first-to-file topical dermatology asset, has been developed using SoliPharma's proprietary platform and will be manufactured at SoliPharma's cGMP-compliant facilities to the regulatory standards of the US FDA,EMA,and UK MHRA in collaboration with Adalvo.
This collaboration represents a significant milestone for both companies — combining SoliPharma's deep expertise in topical and transdermal formulation science with Adalvo's proven track record in bringing complex, high-barrier pharmaceutical products to global markets. Adalvo's focus on scientifically differentiated, technically demanding products made this collaboration a natural fit — and a direct reflection of the standard SoliPharma holds for its commercialisation partners.
Adalvo brings to the partnership an established global commercial infrastructure, with 170+ commercial partnerships across 140+ markets. Unlike generalist distributors, Adalvo's model is built around complex products that require deep regulatory expertise, sophisticated market access strategies, and partners who understand the science. The company will leverage this capability to drive rapid registration, launch, and sustained commercialisation of the product worldwide.
Dr. Sheng Xiaoxia, SoliPharma’s Founder & CEO, commented: " This partnership reflects SoliPharma’s integrated capabilities in complex topical products and our ‘R&D in China,Manufacture for the Globe, Market to the World’ strategy. It represents a powerful endorsement of China’s innovation in advanced topical formulation. In Adalvo, we have found a partner who shares our DNA — their scientific rigor and patient focus align with our shared commitment to advancing clinically proven skin health therapies worldwide."
Anil Okay,CEO, Adalvo, commented: "Complex products demand a different kind of commercialisation partner — one that understands the science, navigates the regulatory landscape with precision, and has the network to move at pace across global markets. That is exactly what Adalvo is built to do. This partnership with SoliPharma reflects our deliberate strategy of working with best-in-class innovators on products that are technically sophisticated and genuinely differentiated."
This licence and supply agreement is intended as the first step in a broader, long-term strategic relationship between Adalvo and SoliPharma. Building on the successful foundation of this initial product, both companies are actively exploring opportunities to expand the collaboration across additional topical and specialty pharmaceutical products, further deepening their joint pipeline and global reach.
About SoliPharma
SoliPharma is a specialty pharmaceutical company dedicated to topical and transdermal innovations for first-to-file, 505(b)(2) and high-barrier complex generics. Building on the cross-disciplines of solid-state science and polymer science, SoliPharma has built a diversified pipeline targeting areas such as acne, atopic dermatitis, and hair disorders. SoliPharma has developed an advanced topical manufacturing facility compliant with China, US, and EU GMP standards. Several of its products have received IND/ANDA approvals in China and/or the US, demonstrating its end-to-end capability from R&D to global commercial launch.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 140 countries and over 170 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by its smart collaboration network and commitment to delivering the highest quality differentiated products and services.
